# Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine

> **NCT00534885** · PHASE4 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 400 (actual)

## Conditions studied

- Hepatitis A

## Interventions

- **BIOLOGICAL:** Healive® Lot 1
- **BIOLOGICAL:** Healive® Lot 2
- **BIOLOGICAL:** Healive® Lot 3
- **BIOLOGICAL:** Havrix

## Key facts

- **NCT ID:** NCT00534885
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00534885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00534885, "Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00534885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*